[{"orgOrder":0,"company":"Medilink","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"YL201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medilink","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medilink \/ Medilink","highestDevelopmentStatusID":"6","companyTruncated":"Medilink \/ Medilink"}]

Find Clinical Drug Pipeline Developments & Deals by Medilink

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : YL201 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Small Cell Lung Carcinoma.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 27, 2025

                          Lead Product(s) : YL201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Amgen Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank